Executive Team

Sharon Cunningham

CO-FOUNDER & CO-CEO

Sharon co-founded Shorla Pharma in 2018 and leads the fundraising and commercialization activities. She has vast experience in equity and debt financing and M&A in the pharmaceutical industry. Sharon is a PwC qualified Chartered Accountant, holds a BSc in Finance from University College Cork and an MBA from University College Dublin Smurfit School. Sharon also sits on the Board of Irish Rule of Law International.

Orlaith
Ryan

CO-FOUNDER & CO-CEO

Orlaith co-founded Shorla Pharma in 2018 and leads the product development programs and supply chain activities. She has vast experience in the life sciences industry, having worked previously in product development, regulation and compliance. Orlaith is a Chartered Scientist, a Biochemist and holds an MSc in Regulatory Affairs from the University of Wales.

VICTORIA POWER

HEAD OF OPERATIONS

Victoria leads the operations team at Shorla Pharma. Having previously held leadership positions at companies such as Novartis and ICON plc, her extensive experience spans programme management, clinical trial operations oversight and product commercialization for both large and small pharma. Victoria has led the development and commercialization of new products in global markets and their associated life cycle management. Victoria has a BSc from University College Dublin and is PRINCE 2 qualified.

JOHN DOHERTY

HEAD OF QUALITY

John joined Shorla Pharma in 2020 and leads the quality operations. He has extensive, practical and up to date international pharmaceutical experience over 30 years where he has held senior quality operations positions. John was involved in the start-up and expansions of both Actavis as Director of Quality at the Dupnitza, Bulgaria site and with Alvogen as VP of Quality. John is registered to act as an EU QP in Ireland. John has a BSc and PhD from University College Dublin and an MBA from Brunel University, London

Board of Directors

Sharon Cunningham

Sharon co-founded Shorla Pharma in 2018 and leads the fundraising and commercialization activities. She has vast experience in equity and debt financing and M&A in the pharmaceutical industry. Sharon is a PwC qualified Chartered Accountant, holds a BSc in Finance from University College Cork and an MBA from University College Dublin Smurfit School. Sharon also sits on the Board of Irish Rule of Law International.

Orlaith
Ryan

Orlaith co-founded Shorla Pharma in 2018 and leads the product development programs and supply chain activities. She has vast experience in the life sciences industry, having worked previously in product development, regulation and compliance. Orlaith is a Chartered Scientist, a Biochemist and holds an MSc in Regulatory Affairs from the University of Wales.

Tom Brennan

Tom previously co-founded pharmaceutical company EirGen Pharma, stability storage company Q1 Scientific and Animal Healthcare company Trivium Vet. Tom has extensive experience in R&D and business development. Within a 10 year period, EirGen Pharma grew from two employees to over 200 people with product sales in almost 50 countries. EirGen was acquired by OPKO for $135m in 2015.

Tom holds a BSc from Cork Institute of Technology, an MSc from University of Manchester and an MBA from University of Limerick. Tom is also a “Qualified Person” as per European Directive 2001/82/EC.

Tom is also a board member of Cork pharmaceutical technology company, Crest Solutions.

Alan O’Connell

Alan is a Partner at Seroba Life Sciences. He has a background in product and business development in the pharmaceutical and biotechnology industries. Prior to joining Seroba, Alan worked at Elan (Dublin), American Biogenetic Sciences, Inc. (New York), and at the Medicines and Healthcare Products Regulatory Agency (London).

Alan has a Ph.D. (neuropharmacology) from the National University of Ireland and has a M.Sc. in pharmacology from the University of London. In addition to the Shorla board, Alan also sits on the boards of Ario Pharma, Crescent Diagnostics and Fusion Pharmaceuticals. He previously sat on the boards of Prexton (acquired by Lundbeck), Veryan (acquired by Otsuka) and Xention (exited via pharma partnerships).

Harcharan (Harry) Singh

Harry is Founder, President and CEO of Glopec International Inc. a privately held international pharmaceutical trading and investment company based in Ontario, Canada. With over 40 years of experience in the pharmaceutical industry, Harry has been the Founding Director and Strategic Investor in several ventures in India, Canada, Ireland and USA. He was previously a non-executive director at EirGen Pharma, Ireland from its inception and has been a Director of Cyanamid India, General Manager and COO of Tata Pharma and Product Group Manager at Warner Lambert Co. subsidiary in India (Warner Hindustan).

Advisory Team

ROLAND TURK MD

COMMERCIAL ADVISOR

Dr Roland Turck is Managing Partner of TurckBio, an international consulting firm focused on corporate strategy as well as on clinical and commercial strategies in oncology and other specialty medicine areas. Roland has gained 25+ years of operational experience as senior biopharm executive in a variety of roles such as President of the Global Specialty Medicine Business Unit at Bayer and as co-founder of an oncology biotech company.

MARTIN F. BEXON MD

CLINICAL ADVISOR

Martin, a UK- and NZ-trained MD, has worked in pharma for 17 years and held positions in the UK, Switzerland and the US leading clinical development programs in oncology, immunology and internal medicine. He has a broad base of experience in the clinic, in early and late clinical development, in medical affairs and across multiple therapy areas.

JOHN H. SAMPSON MD

CLINICAL ADVISOR

John H. Sampson, MD, PhD, is the Robert H. and Gloria Wilkins Distinguished Professor, inaugural chair of the Department of Neurosurgery at Duke University, and the most highly funded PI in neurosurgery by the NIH. In March 2020 he was named president of the Private Diagnostic Clinic, Duke Health’s physician practice of 1,850 providers and 140 clinics. He is a neurosurgeon-scientist who develops novel drugs for patients with brain tumors and focuses on the development, translation, and mechanistic understanding of immunotherapies.